SEC Form 4 · accession 0001209191-19-007869

Biohaven Pharmaceutical Holding Co Ltd. · BHVN

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Director

Period of report

Feb 4, 2019

Accepted (ET)

Feb 6, 2019 · 6:21 pm EST

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001689813

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Shares	Feb 4, 2019	M	10,000	$25.51	A	10,000	I	By Spouse
Common Shares	Feb 4, 2019	M	7,609	$20.79	A	17,609	I	By Spouse
Common Shares^F2	Feb 4, 2019	M	17,609	$42.54	D	0	I	By Spouse

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Employee Stock Option (Right to Buy)^F4,F3	$25.51	Feb 4, 2019	M	10,000	D	—	Aug 3, 2027	Common Shares	10,000	30,000	I
Employee Stock Option (Right to Buy)^F4,F5	$20.79	Feb 4, 2019	M	7,609	D	—	Dec 6, 2027	Common Shares	7,609	22,827	I

F1These exercises and sales were made pursuant to a 10b5-1 trading plan adopted by the Reporting Person's spouse.
F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.54 - $42.56, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
F3The shares underlying this option vest in four equal installments on July 5, 2018, 2019, 2020 and 2021, subject to the optionholder's continuous service with the Issuer at each vesting date.
F4This employee stock option is held by the Reporting Person's spouse.
F5The shares underlying this option vest in four equal installments on December 7, 2018, 2019, 2020 and 2021, subject to the optionholder's continuous service with the Issuer at each vesting date.